Literature DB >> 22726689

Ebselen and congeners inhibit NADPH oxidase 2-dependent superoxide generation by interrupting the binding of regulatory subunits.

Susan M E Smith1, Jaeki Min, Thota Ganesh, Becky Diebold, Tsukasa Kawahara, Yerun Zhu, James McCoy, Aiming Sun, James P Snyder, Haian Fu, Yuhong Du, Iestyn Lewis, J David Lambeth.   

Abstract

NADPH oxidases (Nox) are a primary source of reactive oxygen species (ROS), which function in normal physiology and, when overproduced, in pathophysiology. Recent studies using mice deficient in Nox2 identify this isoform as a novel target against Nox2-implicated inflammatory diseases. Nox2 activation depends on the binding of the proline-rich domain of its heterodimeric partner p22phox to p47phox. A high-throughput screen that monitored this interaction via fluorescence polarization identified ebselen and several of its analogs as inhibitors. Medicinal chemistry was performed to explore structure-activity relationships and to optimize potency. Ebselen and analogs potently inhibited Nox1 and Nox2 activity but were less effective against other isoforms. Ebselen also blocked translocation of p47phox to neutrophil membranes. Thus, ebselen and its analogs represent a class of compounds that inhibit ROS generation by interrupting the assembly of Nox2-activating regulatory subunits.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22726689      PMCID: PMC3383625          DOI: 10.1016/j.chembiol.2012.04.015

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  81 in total

Review 1.  The pharmacology of ebselen.

Authors:  M J Parnham; S Leyck; E Graf; E J Dowling; D R Blake
Journal:  Agents Actions       Date:  1991-01

2.  Assembly and activation of the phagocyte NADPH oxidase. Specific interaction of the N-terminal Src homology 3 domain of p47phox with p22phox is required for activation of the NADPH oxidase.

Authors:  H Sumimoto; K Hata; K Mizuki; T Ito; Y Kage; Y Sakaki; Y Fukumaki; M Nakamura; K Takeshige
Journal:  J Biol Chem       Date:  1996-09-06       Impact factor: 5.157

3.  Cell transformation by the superoxide-generating oxidase Mox1.

Authors:  Y A Suh; R S Arnold; B Lassegue; J Shi; X Xu; D Sorescu; A B Chung; K K Griendling; J D Lambeth
Journal:  Nature       Date:  1999-09-02       Impact factor: 49.962

4.  Identification of the maturation factor for dual oxidase. Evolution of an eukaryotic operon equivalent.

Authors:  Helmut Grasberger; Samuel Refetoff
Journal:  J Biol Chem       Date:  2006-05-01       Impact factor: 5.157

Review 5.  Molecular actions of ebselen--an antiinflammatory antioxidant.

Authors:  T Schewe
Journal:  Gen Pharmacol       Date:  1995-10

6.  Strong inhibition of mammalian lipoxygenases by the antiinflammatory seleno-organic compound ebselen in the absence of glutathione.

Authors:  C Schewe; T Schewe; A Wendel
Journal:  Biochem Pharmacol       Date:  1994-07-05       Impact factor: 5.858

7.  Inhibition of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the inactivation by ebselen of a critical thiol essential for the catalytic activity of nitric oxide synthase.

Authors:  A Zembowicz; R J Hatchett; W Radziszewski; R J Gryglewski
Journal:  J Pharmacol Exp Ther       Date:  1993-12       Impact factor: 4.030

8.  Nox regulation of smooth muscle contraction.

Authors:  Darren R Ritsick; William A Edens; Victoria Finnerty; J David Lambeth
Journal:  Free Radic Biol Med       Date:  2007-03-12       Impact factor: 7.376

Review 9.  Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets.

Authors:  Vincent Jaquet; Leonardo Scapozza; Robert A Clark; Karl-Heinz Krause; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2009-10       Impact factor: 8.401

10.  Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury.

Authors:  Yumiko Imai; Keiji Kuba; G Greg Neely; Rubina Yaghubian-Malhami; Thomas Perkmann; Geert van Loo; Maria Ermolaeva; Ruud Veldhuizen; Y H Connie Leung; Hongliang Wang; Haolin Liu; Yang Sun; Manolis Pasparakis; Manfred Kopf; Christin Mech; Sina Bavari; J S Malik Peiris; Arthur S Slutsky; Shizuo Akira; Malin Hultqvist; Rikard Holmdahl; John Nicholls; Chengyu Jiang; Christoph J Binder; Josef M Penninger
Journal:  Cell       Date:  2008-04-18       Impact factor: 41.582

View more
  37 in total

Review 1.  NOX Modifiers-Just a Step Away from Application in the Therapy of Airway Inflammation?

Authors:  Joanna Wieczfinska; Milena Sokolowska; Rafal Pawliczak
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 2.  New insights on NOX enzymes in the central nervous system.

Authors:  Zeynab Nayernia; Vincent Jaquet; Karl-Heinz Krause
Journal:  Antioxid Redox Signal       Date:  2014-01-16       Impact factor: 8.401

3.  New insights into the roles of NADPH oxidases in sexual development and ascospore germination in Sordaria macrospora.

Authors:  Daniela Elisabeth Dirschnabel; Minou Nowrousian; Nallely Cano-Domínguez; Jesus Aguirre; Ines Teichert; Ulrich Kück
Journal:  Genetics       Date:  2014-01-09       Impact factor: 4.562

4.  High-Throughput Screening of NOX Inhibitors.

Authors:  Jacek Zielonka; Monika Zielonka; Gang Cheng; Micael Hardy; Balaraman Kalyanaraman
Journal:  Methods Mol Biol       Date:  2019

Review 5.  Cysteine-mediated redox signaling: chemistry, biology, and tools for discovery.

Authors:  Candice E Paulsen; Kate S Carroll
Journal:  Chem Rev       Date:  2013-03-20       Impact factor: 60.622

Review 6.  Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2.

Authors:  Federico Carbone; Priscila Camillo Teixeira; Vincent Braunersreuther; François Mach; Nicolas Vuilleumier; Fabrizio Montecucco
Journal:  Antioxid Redox Signal       Date:  2014-04-22       Impact factor: 8.401

Review 7.  Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors.

Authors:  M Eugenia Cifuentes-Pagano; Daniel N Meijles; Patrick J Pagano
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

8.  Thioxo-dihydroquinazolin-one Compounds as Novel Inhibitors of Myeloperoxidase.

Authors:  Yang Li; Thota Ganesh; Becky A Diebold; Yerun Zhu; James W McCoy; Susan M E Smith; Aiming Sun; J David Lambeth
Journal:  ACS Med Chem Lett       Date:  2015-08-31       Impact factor: 4.345

Review 9.  Microvascular NADPH oxidase in health and disease.

Authors:  Yao Li; Patrick J Pagano
Journal:  Free Radic Biol Med       Date:  2017-03-06       Impact factor: 7.376

10.  Bridged tetrahydroisoquinolines as selective NADPH oxidase 2 (Nox2) inhibitors.

Authors:  Eugenia Cifuentes-Pagano; Jaideep Saha; Gábor Csányi; Imad Al Ghouleh; Sanghamitra Sahoo; Andrés Rodríguez; Peter Wipf; Patrick J Pagano; Erin M Skoda
Journal:  Medchemcomm       Date:  2013-07       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.